Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... breaking presentation at the European Society for Medical Oncology (ESMO). Sanofi said the results are strong ...

In the Phase II MAIA lung cancer trial, THIO improved patients’ overall survival when taken in combination with Libtayo.

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Detailed results will be presented at an upcoming medical meeting and will be shared with regulatory ... research across diverse stages of skin cancer.” The potential use of Libtayo described above is ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

These findings are expected to be presented at a medical conference and submitted to the U.S. Food and Drug Administration (FDA) in the first half of 2025. Libtayo ... use, and its safety and ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically ...

The unapproved uses of EYLEA, EYLEA HD ... These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA ...